March 09, 2026 — 7 articles reviewed
This cycle’s dominant story is a single Cambridge University study linking recreational drug use to significantly elevated stroke risk, particularly in younger populations, which received extensive media coverage across multiple major outlets. Alongside that, infrastructure expansion in Texas and a closer look at edible cannabis pharmacokinetics round out a feed that balances safety concerns with practical access and dosing realities.
The Cambridge stroke data is a reminder that cannabis carries real cardiovascular risk that we must communicate honestly, especially to younger patients who assume safety from legality. Good medicine means holding two truths at once: cannabis has genuine therapeutic value for many patients, and it demands the same individualized risk assessment we apply to every other intervention in our toolkit.
Have thoughts on this? Share it:
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
